FGF-23 Linked to Cinacalcet Use
Fibroblast growth factor 23 (FGF-23) is positively associated with cinacalcet use, calcium, and phosphorus in hemodialysis (HD) patients, according to a study presented at Renal Week 2010 in Denver.
Renal Week 2010 Secondary Hyperparathyroidism
SHPT in Dialysis Patients Associated with Greater Mortality, Morbidity
New data presented at Renal Week 2010 in Denver confirm the high morbidity and mortality associated with secondary hyperparathyroidism (SHPT) in dialysis patients, emphasizing the need for early referral as well as other therapeutic interventions.
Oral Paricalcitol May Have Similar Efficacy to Oral Calcitriol
Oral paricalcitol (OP) appears to have similar efficacy and safety compared with oral calcitriol (OC) in dialysis patients with secondary hyperparathyroidism (SHPT), according to results from a randomized, controlled trial presented at Renal Week 2010 in Denver.
Cinacalcet for SHPT Safe, Effective in Renal Transplant Recipients
Cinacalcet is a safe and effective option for treating hypocalcemia and secondary hyperparathyroidism (SHPT) in renal transplant recipients, according to a new German study presented at Renal Week 2010 in Denver.
Parathyroidectomies Decline in Japan After Cinacalcet Introduced
Since the commercial availability of cinacalcet in Japan in 2008, the frequency of parathyroidectomy (PTx) in hemodialysis (HD) patients has decreased, according to researchers who presented their finsings at Renal Week 2010 in Denver.
Metabolic Syndrome in CKD Patients May Be Linked to PTH
Higher parathyroid hormone (PTH) levels are associated with an increased prevalence of metabolic syndrome in non-diabetic patients with CKD, according to data shown at Renal Week 2010 in Denver.
Elevated PTH May Increase Short-Term Mortality Risk in CKD Patients
Higher parathyroid hormone (PTH) levels are associated with an increased risk of death, possibly because of a higher prevalence of metabolic syndrome as well as other possible pathways according to a study presented at Renal Week 2010 in Denver.
Elevated iPTH Hikes Cardiovascular Event Risk in CKD Patients
Elevated levels of serum intact parathyroid hormone (iPTH) in patients with stage III and IV CKD may be associated with an increase in the risk of cardiovascular (CV) events, according to a new study presented at REnal Week 2010 in Denver.
Cinacalcet May Reduce Mortality in HD Patients with SHPT
Cinacalcet may help reduce mortality in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT) in the “real world,” Japanese researchers reported at Renal Week 2010 in Denver.
Post Kidney Transplant Parathyroidectomy May Affect Graft Function
Post kidney transplant parathyroidectomy (PTx) may cause a transient decline in estimated glomerular filtration rate (eGFR) during the first few months but substantially improves to a level significantly superior to pre-PTx values, according to data shown at Renal Week 2010 in Denver.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...